Cargando…

局部放疗联合化疗在广泛期小细胞肺癌患者中的作用

BACKGROUND AND OBJECTIVE: Chemotherapy is a highly efficient primary treatment for extensive-stage small cell lung cancer (ES-SCLC). However, patients receiving such treatment are prone to develop drug resistance. Local treatment is palliative and thus can alleviate the local symptoms and improve qu...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015215/
https://www.ncbi.nlm.nih.gov/pubmed/25975297
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.05.04
_version_ 1783334365442342912
collection PubMed
description BACKGROUND AND OBJECTIVE: Chemotherapy is a highly efficient primary treatment for extensive-stage small cell lung cancer (ES-SCLC). However, patients receiving such treatment are prone to develop drug resistance. Local treatment is palliative and thus can alleviate the local symptoms and improve quality of life, but limited evidence is available for prolonging survival. Hence, this study evaluated the role of local treatment in chemotherapy of patients with ES-SCLC. METHODS: A total of 302 ES-SCLC cases were enrolled in this retrospective study. Prognostic factors were analyzed by Kaplan-Meier and Cox multivariate proportional hazards model. RESULTS: Median progression-free survival (PFS) and median survival time (MST) of the patients were 4.4 and 10.4 months, respectively. 1-, 2-, and 3-year survival rates were 37.8%, 10.2% and 4.4%, correspondingly. The MST of the primary tumor radiotherapy plus chemotherapy group was 14.3 months, whereas that of the chemotherapy group was 8.2 months (P < 0.01). The MSTs of multiple-site, single-site, and non-metastasis local treatments were 18.7, 12.3 and 8.9 months, respectively (P < 0.01). The MSTs of initiative, passive, and non-metastasis local treatments were 16.0, 10.9 and 9.4 months, correspondingly (P < 0.01). The MSTs of patients with prophylactic cranial irradiation (PCI) and those without PCI were 19.8 and 9.9 months, respectively (P < 0.01). Primary tumor radiotherapy, metastasis local treatment, and PCI were independent prognostic factors for ES-SCLC. CONCLUSION: Primary tumor radiotherapy, metastasis local treatment, and PCI can significantly improve survival in patients with ES-SCLC.
format Online
Article
Text
id pubmed-6015215
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60152152018-07-06 局部放疗联合化疗在广泛期小细胞肺癌患者中的作用 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Chemotherapy is a highly efficient primary treatment for extensive-stage small cell lung cancer (ES-SCLC). However, patients receiving such treatment are prone to develop drug resistance. Local treatment is palliative and thus can alleviate the local symptoms and improve quality of life, but limited evidence is available for prolonging survival. Hence, this study evaluated the role of local treatment in chemotherapy of patients with ES-SCLC. METHODS: A total of 302 ES-SCLC cases were enrolled in this retrospective study. Prognostic factors were analyzed by Kaplan-Meier and Cox multivariate proportional hazards model. RESULTS: Median progression-free survival (PFS) and median survival time (MST) of the patients were 4.4 and 10.4 months, respectively. 1-, 2-, and 3-year survival rates were 37.8%, 10.2% and 4.4%, correspondingly. The MST of the primary tumor radiotherapy plus chemotherapy group was 14.3 months, whereas that of the chemotherapy group was 8.2 months (P < 0.01). The MSTs of multiple-site, single-site, and non-metastasis local treatments were 18.7, 12.3 and 8.9 months, respectively (P < 0.01). The MSTs of initiative, passive, and non-metastasis local treatments were 16.0, 10.9 and 9.4 months, correspondingly (P < 0.01). The MSTs of patients with prophylactic cranial irradiation (PCI) and those without PCI were 19.8 and 9.9 months, respectively (P < 0.01). Primary tumor radiotherapy, metastasis local treatment, and PCI were independent prognostic factors for ES-SCLC. CONCLUSION: Primary tumor radiotherapy, metastasis local treatment, and PCI can significantly improve survival in patients with ES-SCLC. 中国肺癌杂志编辑部 2015-05-20 /pmc/articles/PMC6015215/ /pubmed/25975297 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.05.04 Text en 版权所有©《中国肺癌杂志》编辑部2015 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
局部放疗联合化疗在广泛期小细胞肺癌患者中的作用
title 局部放疗联合化疗在广泛期小细胞肺癌患者中的作用
title_full 局部放疗联合化疗在广泛期小细胞肺癌患者中的作用
title_fullStr 局部放疗联合化疗在广泛期小细胞肺癌患者中的作用
title_full_unstemmed 局部放疗联合化疗在广泛期小细胞肺癌患者中的作用
title_short 局部放疗联合化疗在广泛期小细胞肺癌患者中的作用
title_sort 局部放疗联合化疗在广泛期小细胞肺癌患者中的作用
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015215/
https://www.ncbi.nlm.nih.gov/pubmed/25975297
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.05.04
work_keys_str_mv AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng
AT júbùfàngliáoliánhéhuàliáozàiguǎngfànqīxiǎoxìbāofèiáihuànzhězhōngdezuòyòng